COLUMBUS 7-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma

We report results from the 7-year analysis of COLUMBUS part 1 (NCT01909453) at 99.7 months (median duration between randomization and data cutoff).

Source: European Journal of Cancer - April 24, 2024 Category: Cancer & Oncology Authors: Dirk Schadendorf, Reinhard Dummer, Keith T. Flaherty, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen J. Gogas, Ralf Gutzmer, Ivana Krajsov á, Gabriella Liszkay, Carmen Loquai, Mario Mandalà, Naoya Yamazaki, Paola Queirolo, Carol Tags: Original Research Source Type: research